Toxoplasmic encephalitis during mycophenolate mofetil immunotherapy of neuromuscular disease

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 1, 2015, Pages

  Bernardo, Danilo R ^a   Chahin, Nizar ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; FOLINIC ACID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYCOPHENOLATE MOFETIL; PREDNISONE; PROTEIN; PYRIDOSTIGMINE; PYRIMETHAMINE; RITUXIMAB; SULFADIAZINE;

ABDOMINAL RADIOGRAPHY; AGED; ANTIPARASITIC THERAPY; ARTICLE; ATAXIC APHASIA; BRAIN DISEASE; BRAIN EDEMA; CASE REPORT; CD4 LYMPHOCYTE COUNT; CEREBRAL TOXOPLASMOSIS; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DRUG WITHDRAWAL; ELECTROMYOGRAM; FEMALE; FEVER; GAIT DISORDER; HEMIPARESIS; HUMAN; HYPERREFLEXIA; IMMUNOTHERAPY; LIMB WEAKNESS; LONG TERM CARE; MALE; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYOSITIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS RADIOGRAPHY; PLEOCYTOSIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; REAL TIME POLYMERASE CHAIN REACTION; THORAX RADIOGRAPHY; TOXOPLASMA GONDII;

EID: 84945284496     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000063     Document Type: Article

References (20)

1. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005;14(SUPPL. 1):s2-s8.
2. Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttinic P, Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev 2007;6:190-195.
3. Gallino A, Maggiorini M, Kiowski W, et al. Toxoplasmosis in heart transplant recipients. Eur J Clin Microbiol Infect Dis 1996;15:389-393.
4. Renoult E, Georges E, Biava MF, et al. Toxoplasmosis in kidney transplant recipients: report of six cases and review. Clin Infect Dis 1997;24:625-634.
5. Mele A, Paterson PJ, Prentice HG, Leoni P, Kibbler CC. Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature. Bone Marrow Transplant 2002;29:691-698.
6. Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med 2005;353: 1530-1531.
7. Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology 2014;53:284-284.
8. Safa G, Darrieux L. Cerebral toxoplasmosis after rituximab therapy. JAMA Intern Med 2013;173:924-926.
9. Zecca C, Nessi F, Bernasconi E, Gobbi C. Ocular toxoplasmosis during natalizumab treatment. Neurology 2009; 73:1418-1419.
10. Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol 2001;154:357-365.
11. Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol 2009;39:1385-1394.
12. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004; 363:1965-1976.
13. Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58:1-207; quiz CE1-4.
14. Nissapatorn V, Lee C, Quek KF, Leong CL, Mahmud R, Abdullah KA. Toxoplasmosis in HIV/AIDS patients: a current situation. Jpn J Infect Dis 2004;57:160-165.
15. Martina M-N, Cervera C, Esforzado N, et al. Toxoplasma gondii primary infection in renal transplant recipients. Two case reports and literature review. Transpl Int 2010;24:e6-e12.
16. Ruyssen-Witrand A, Fautrel B, Saraux A, Le-Loët X, Pham T. Infections induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2010;77:246-251.
17. Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000;14:136-138.
18. Pisoni CN, Sanchez FJ, Karim Y, et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005;32:1047-1052.
19. Stamp LK, Hurst M. Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases? J Rheumatol 2010;37:686-688.
20. Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 2013;88:83-105.